EGFR and breast cancer: Based on the binding affinities as exhibited by the docking studies supported by the in-vitro assays, the current study comes to the conclusion that the five selected furanocoumarin compounds i.e. XAN, BER, ANG, PSO and IMP can be considered as potent anti-breast cancer agents against ERα, PR, EGFR and mTOR.